(RAPT) RAPT Therapeutics - Ratings and Ratios
Zelnecirnon, Tivumecirnon, CCR4 Antagonist, Oral Small Molecule
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 117% |
| Value at Risk 5%th | 152% |
| Relative Tail Risk | -20.45% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.72 |
| Alpha | 244.46 |
| CAGR/Max DD | -0.48 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.489 |
| Beta | 1.223 |
| Beta Downside | 1.602 |
| Drawdowns 3y | |
|---|---|
| Max DD | 97.57% |
| Mean DD | 69.78% |
| Median DD | 87.04% |
Description: RAPT RAPT Therapeutics January 17, 2026
RAPT Therapeutics (NASDAQ:RAPT) is a clinical-stage biotech focused on oral small-molecule drugs that modulate CCR4, a chemokine receptor implicated in both oncology and inflammatory disorders. Its lead inflammation candidate, zelnecirnon (RPT193), aims to block type-2 helper T-cell trafficking, while its oncology lead, tivumecirnon (FLX475), is being evaluated in a Phase 1/2 trial both as monotherapy and in combination with pembrolizumab for advanced cancers. The firm, incorporated in 2015 and headquartered in South San Francisco, rebranded from FLX Bio in 2019.
As of the most recent 10-Q (Q3 2024), RAPT reported cash and cash equivalents of roughly $48 million, providing an estimated 12-month runway at its current burn rate of $4-5 million per quarter. The CCR4 target aligns with a broader industry shift toward oral immunomodulators, which historically command higher patient adherence and lower administration costs than biologics-a factor driving a 7 % CAGR in the oral oncology market over the past five years. However, the company’s valuation is highly sensitive to trial outcomes, given the absence of any approved products and a current market cap of about $120 million, implying a price-to-cash ratio near 2.5×.
For a deeper quantitative view, the ValueRay platform offers tools that can help you model RAPT’s risk-adjusted upside and compare it to sector peers.
Piotroski VR‑10 (Strict, 0-10) 0.0
| error: Net Income check cannot be calculated (needs Net Income TTM and Revenue TTM) |
| FCFTA -0.52 (>2.0%) and ΔFCFTA 40.65pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| error: NWC/Revenue cannot be calculated (needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.52 (>3.0%) and CFO -86.6m > Net Income -105.6m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 12.04 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (27.0m) change vs 12m ago 454.5% (target <= -2.0% for YES) |
| error: Gross Margin (current vs previous) cannot be calculated (needs Total Revenue and Cost Of Revenue) |
| Asset Turnover 0.0% (prev 4.88%; Δ -4.88pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -32.86 (EBITDA TTM -108.0m / Interest Expense TTM -3.32m) >= 6 (WARN >= 3) |
Altman Z'' -63.49
| (A) 0.89 = (Total Current Assets 161.0m - Total Current Liabilities 13.4m) / Total Assets 165.7m |
| (B) -4.02 = Retained Earnings (Balance) -666.9m / Total Assets 165.7m |
| warn (B) unusual magnitude: -4.02 — check mapping/units |
| (C) -0.79 = EBIT TTM -109.0m / Avg Total Assets 137.1m |
| (D) -48.45 = Book Value of Equity -666.8m / Total Liabilities 13.8m |
| Total Rating: -63.49 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 27.94
| 1. Piotroski 0.0pt |
| 2. FCF Yield -11.75% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.02 |
| 5. Debt/Ebitda 0.33 |
| 6. ROIC - WACC (= -60.88)% |
| 7. RoE -61.81% |
| 8. Rev. Trend -32.46% |
| 9. EPS Trend 9.24% |
What is the price of RAPT shares?
Over the past week, the price has changed by +4.40%, over one month by +3.14%, over three months by +21.33% and over the past year by +268.70%.
Is RAPT a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 4
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the RAPT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 68.8 | 95.9% |
| Analysts Target Price | 68.8 | 95.9% |
| ValueRay Target Price | 30.3 | -13.6% |
RAPT Fundamental Data Overview January 17, 2026
P/B = 5.8694
Revenue TTM = 0.0 USD
EBIT TTM = -109.0m USD
EBITDA TTM = -108.0m USD
Long Term Debt = 2.60m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.21m USD (from shortTermDebt, last quarter)
Debt = 2.60m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -35.3m USD (from netDebt column, last quarter)
Enterprise Value = 737.3m USD (892.0m + Debt 2.60m - CCE 157.3m)
Interest Coverage Ratio = -32.86 (Ebit TTM -109.0m / Interest Expense TTM -3.32m)
EV/FCF = -8.51x (Enterprise Value 737.3m / FCF TTM -86.7m)
FCF Yield = -11.75% (FCF TTM -86.7m / Enterprise Value 737.3m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 200.0k) / Revenue TTM)
Tobins Q-Ratio = 4.45 (Enterprise Value 737.3m / Total Assets 165.7m)
Interest Expense / Debt = 88.25% (Interest Expense 2.29m / Debt 2.60m)
Taxrate = 21.0% (US default 21%)
NOPAT = -86.1m (EBIT -109.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 12.04 (Total Current Assets 161.0m / Total Current Liabilities 13.4m)
Debt / Equity = 0.02 (Debt 2.60m / totalStockholderEquity, last quarter 152.0m)
Debt / EBITDA = 0.33 (negative EBITDA) (Net Debt -35.3m / EBITDA -108.0m)
Debt / FCF = 0.41 (negative FCF - burning cash) (Net Debt -35.3m / FCF TTM -86.7m)
Total Stockholder Equity = 170.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -77.05% (Net Income -105.6m / Total Assets 165.7m)
RoE = -61.81% (Net Income TTM -105.6m / Total Stockholder Equity 170.9m)
RoCE = -62.79% (EBIT -109.0m / Capital Employed (Equity 170.9m + L.T.Debt 2.60m))
RoIC = -50.36% (negative operating profit) (NOPAT -86.1m / Invested Capital 170.9m)
WACC = 10.52% (E(892.0m)/V(894.6m) * Re(10.55%) + (debt cost/tax rate unavailable))
Discount Rate = 10.55% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 137.1%
Fair Price DCF = unknown (Cash Flow -86.7m)
EPS Correlation: 9.24 | EPS CAGR: -1.61% | SUE: -1.53 | # QB: 0
Revenue Correlation: -32.46 | Revenue CAGR: -21.08% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.69 | Chg30d=+0.043 | Revisions Net=-1 | Analysts=5
EPS next Year (2026-12-31): EPS=-3.21 | Chg30d=+0.139 | Revisions Net=-3 | Growth EPS=-27.9% | Growth Revenue=+0.0%
Additional Sources for RAPT Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle